...
首页> 外文期刊>The oncologist >Suspected Hereditary Cancer Syndromes in Young Patients: Heterogeneous Clinical and Genetic Presentation of Colorectal Cancers
【24h】

Suspected Hereditary Cancer Syndromes in Young Patients: Heterogeneous Clinical and Genetic Presentation of Colorectal Cancers

机译:涉嫌遗传性癌症综合征患者:结直肠癌的异质临床和遗传介绍

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Colorectal cancer (CRC) is rare in young patients without a confirmed family history of cancer. Reports of an increased prevalence of POLD1 / POLE mutations in young patients with colorectal cancer have raised awareness and support routine genetic testing for patients with early-onset tumors. In cases of CRC without proven MMR -germline mutation, molecular analyses are warranted to confirm or rule out other familial CRC syndromes. This article describes the cases of two young male patients, who presented with locally advanced and metastatic CRC, and reports the results of the germline mutational analyses done for both patients. These cases demonstrate the importance of special care and molecular diagnostic procedures for young patients with CRC. Key Points Patients with colorectal cancer who are younger than 50 years at initial diagnosis (early onset) should routinely undergo genetic testing. Early- and very-early-onset patients (younger than 40 years) with absence of microsatellite instability should be considered for tumor mutation burden testing and/or DNA polymerase proofreading mutation. The mutational signature of HSP110 within mismatch repair deficiency-related tumors may help to identify patients likely to benefit from 5-fluorouracil-based chemotherapy. Intensified, maintained, and specific surveillance may help to reduce secondary tumor progression.
机译:在没有证实家族癌症的患者中,结肠直肠癌(CRC)很少见。报告患有结直肠癌患者的Pold1 /杆突变患病率增加提高了提高认识和支持早期肿瘤患者的常规遗传学检测。在CRC的情况下,没有经过验证的MMR -Germline突变,保证分子分析确认或排除其他家庭CRC综合征。本文介绍了呈现局部晚期和转移CRC的两名年轻男性患者的病例,并报告了两种患者的种系突变分析结果。这些病例表明了特殊护理和分子诊断程序对CRC患者的重要性。在初步诊断(早期发作)术语患者患有年龄较小的关键点患者,应常规地进行遗传检测。对于肿瘤突变负荷测试和/或DNA聚合酶校对突变,应考虑没有微卫星不稳定性的早期和非常早期发病患者(小于40岁)。 HSP110内的失配维修缺乏相关肿瘤的突变签名可能有助于识别可能从5-氟尿基化疗中受益的患者。强化,维持和特定监测可能有助于减少次生肿瘤进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号